Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ALTA3263 |
| Synonyms | |
| Therapy Description |
ALTA3263 is a an isoform-selective inhibitor of KRAS with activity against KRAS G12C, KRAS G12D, and KRAS G12V, which reduces downstream signaling and potentially decreases tumor cell viability and tumor growth (Eur J Cancer 211 (2024): 114537). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ALTA3263 | ALTA-3263|ALTA 3263 | KRAS G12C inhibitor 36 KRAS G12D Inhibitor 25 | ALTA3263 is a an isoform-selective inhibitor of KRAS with activity against KRAS G12C, KRAS G12D, and KRAS G12V, which reduces downstream signaling and potentially decreases tumor cell viability and tumor growth (Eur J Cancer 211 (2024): 114537). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06835569 | Phase I | ALTA3263 ALTA3263 + Cetuximab | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | Recruiting | USA | 0 |